holshu
ml
debolt
c
lindquist
et
al
first
case
novel
coronaviru
unit
state
n
engl
j
med
publish
onlin
jan
http
lai
st
treatment
sever
acut
respiratori
syndrom
eur
j
clin
microbiol
infect
di
soo
yo
cheng
wong
r
et
al
retrospect
comparison
convalesc
plasma
continu
highdos
methylprednisolon
treatment
sar
patient
control
nurs
guangdong
second
provinci
gener
hospit
undergon
intens
train
becom
familiar
requir
infect
control
neg
pressur
isol
ward
herein
camera
cover
entir
ward
except
privaci
area
infect
control
observ
monitor
medic
staff
real
time
via
comput
monitor
separ
area
figur
main
respons
observ
maintain
normal
oper
neg
pressur
isol
ward
supervis
implement
disinfect
ensur
suffici
suppli
protect
materi
arrang
specimen
inspect
reliev
anxieti
medic
personnel
treat
patient
observ
pay
attent
medic
staff
time
neg
pressur
ward
also
put
take
protect
equip
enter
leav
ward
although
healthcar
provid
attend
multipl
train
session
emerg
drill
oper
especi
highstress
neg
pressur
ward
step
might
omit
overlook
thu
incur
potenti
exposur
nosocomi
infect
exampl
nurs
help
elderli
patient
pull
zipper
neg
pressur
ward
zipper
unexpectedli
rip
nurs
glove
nurs
becam
nervou
anxiou
continu
procedur
discov
situat
screen
observ
immedi
sooth
nurs
sent
anoth
staff
member
ward
assist
follow
occup
exposur
process
observ
instruct
nurs
remov
glove
care
disinfect
hand
dispos
rip
glove
observ
also
systemat
assess
risk
nurs
arrang
quarantin
room
medic
observ
ensur
full
safeti
allow
return
neg
pressur
ward
observ
system
proactiv
infect
control
tool
provid
immedi
prevent
nosocomi
infect
neg
pressur
isol
ward
offer
creativ
assist
combat
outbreak
guangdong
second
provinci
gener
hospit
plan
incorpor
artifici
intellig
imag
recognit
observ
system
aim
enhanc
sensit
accuraci
instant
detect
implement
improv
observ
system
might
promis
endeavor
control
nosocomi
infect
outbreak
acut
infecti
diseas
declar
compet
interest
outbreak
sever
acut
respiratori
syndrom
coronaviru
origin
wuhan
china
becom
major
concern
world
pneumonia
induc
name
coronaviru
diseas
feb
viru
affect
peopl
worldwid
caus
death
date
specif
treatment
proven
effect
infect
apart
support
care
oxygen
suppli
mild
case
extracorpor
membran
oxygen
critic
ill
patient
specif
drug
diseas
still
research
usa
first
patient
infect
treat
support
care
intraven
remdesivir
patient
recov
discharg
howev
randomis
clinic
trial
need
evalu
safeti
efficaci
remdesivir
treatment
convalesc
plasma
immunoglobulin
use
last
resort
improv
surviv
rate
patient
sar
whose
condit
continu
deterior
despit
treatment
puls
methylprednisolon
moreov
sever
studi
show
shorter
hospit
stay
lower
mortal
patient
treat
convalesc
plasma
treat
convalesc
plasma
use
convalesc
plasma
collect
patient
recov
ebola
viru
diseas
recommend
empir
treatment
outbreak
protocol
use
convalesc
plasma
treatment
middl
east
respiratori
syndrom
coronaviru
establish
term
patient
pandem
influenza
viru
infect
prospect
cohort
studi
hung
colleagu
show
signific
reduct
rel
risk
mortal
odd
ratio
ci
patient
treat
convalesc
plasma
addit
subgroup
analysi
viral
load
convalesc
plasma
treatment
significantli
lower
day
intens
care
unit
admiss
advers
event
observ
multicentr
prospect
doubleblind
randomis
control
trial
hung
colleagu
show
use
convalesc
plasma
patient
recov
influenza
viru
infect
treat
patient
sever
influenza
infect
associ
lower
viral
load
reduc
mortal
within
day
symptom
onset
metaanalysi
mairjenkin
colleagu
show
mortal
reduc
receiv
variou
dose
convalesc
plasma
patient
sever
acut
respiratori
infec
tion
advers
event
complic
treatment
anoth
metaanalysi
luke
colleagu
identifi
eight
studi
involv
patient
influenzapneumonia
receiv
infus
influenzaconvalesc
human
blood
product
show
pool
absolut
reduct
ci
p
overal
crude
casefat
rate
low
risk
bia
one
possibl
explan
efficaci
convalesc
plasma
therapi
antibodi
convalesc
plasma
might
suppress
viraemia
schoof
colleagu
report
immuno
therapi
broad
neutralis
antibodi
enhanc
host
humor
immun
vivo
trial
also
show
effect
antibodi
limit
free
viral
clearanc
block
new
infect
also
includ
acceler
infect
cell
clearanc
viraemia
peak
first
week
infect
viral
ill
patient
usual
develop
primari
immun
respons
day
follow
viru
clearanc
therefor
theoret
effect
administ
convalesc
plasma
earli
stage
diseas
howev
treatment
might
effect
relationship
convalesc
plasma
antibodi
level
includ
antivir
drug
steroid
intraven
immunoglobulin
accord
manag
mainli
focus
infect
prevent
case
detect
monitor
support
care
howev
specif
treatment
recommend
absenc
evid
importantli
current
guidelin
emphasis
systemat
corticosteroid
given
routin
treatment
also
recommend
commnt
lancet
evid
show
convalesc
plasma
patient
recov
viral
infect
use
treatment
without
occurr
sever
advers
event
therefor
might
worthwhil
test
safeti
efficaci
con
valesc
plasma
transfus
patient
coronaviru
diseas
sever
acut
respiratori
syndrom
sar
characteris
overexuber
inflammatori
respons
sar
viral
load
correl
worsen
symptom
previou
correspond
lancet
describ
benevolentai
proprietari
artifici
intellig
ai
deriv
knowledg
graph
queri
suit
algorithm
enabl
identif
target
potenti
therapeut
sar
coronaviru
caus
organ
identifi
group
approv
drug
could
inhibit
clathrinmedi
endocytosi
therebi
inhibit
viral
infect
cell
appendix
drug
target
member
numbassoci
kinas
nak
familyinclud
gakth
inhibit
shown
reduc
viral
infect
vitro
baricitinib
identifi
nak
inhibitor
particularli
high
affin
pivot
regul
clathrinmedi
endocytosi
suggest
drug
could
use
counter
infect
subject
appropri
clinic
test
take
work
short
timescal
necess
deal
new
human
pathogen
reexamin
affin
select
approv
drug
knowledg
graph
identifi
antivir
antiinflammatori
properti
drug
predict
particular
import
treatment
sever
case
host
inflammatori
respons
becom
major
caus
lung
damag
subsequ
mortal
comparison
properti
three
best
candid
shown
tabl
baricitinib
fedratinib
ruxolitinib
potent
select
jak
inhibitor
approv
indic
rheumatoid
arthriti
myelofibrosi
three
power
antiinflammatori
jakstat
signal
inhibitor
like
effect
consequ
elev
level
cytokin
includ
typic
observ
peopl
although
three
candid
similar
jak
inhibitor
potenc
high
affin
suggest
baricitinib
best
group
especi
given
oncedaili
oral
dose
accept
sideeffect
profil
signific
sideeffect
seen
patientyear
clinic
trial
programm
use
european
medicin
agenc
registr
small
increas
upper
respiratori
tract
infect
similar
observ
methotrex
incid
seriou
infect
eg
herp
zoster
week
dose
small
per
patientyear
similar
placebo
use
agent
patient
day
exampl
suggest
sideeffect
would
trivial
aialgorithmpredict
nak
inhibitor
includ
combin
oncolog
drug
sunitinib
